Navigation Links
Yale researchers explain why cancer 'smart drugs' may not be so smart
Date:5/11/2011

Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor (EGFR), and found that a decoy receptor might be limiting the amount of drug that gets to the intended target.

"We know that smart drugs like Cetuximab are not always effective in the cancer cells they're supposed to target because there are no positive predictive markers for selecting the patients who will benefit from treatment with EGFR-targeted therapies, including EGFR itself," said lead author Nita Maihle, professor in the Departments of Obstetrics, Gynecology & Reproductive Sciences and of Pathology at Yale School of Medicine. "Why would a patient be given an expensive drug if it doesn't work? Our studies provide new insight into this paradoxical EGFR testing conundrum."

In a study published recently in the journal Cancer, Maihle and her team isolated a protein from human blood that looks like EGFR, but is actually a closely related variant called serum sEGFR. They showed that Cetuximab binds equally as well to serum sEGFR as it does to the intended EGFR cancer target.

Those study results showed that sEGFR might act as a decoy receptor in the blood of cancer patients, tying up Cetuximab and therefore limiting the amount of Cetuximab that actually gets to the intended target.

Such limitations may, in part, provide an explanation for the failure of two large phase III clinical trials on Cetuximab in colorectal cancer patients, since serum sEGFR concentrations are highly variable in cancer patients. These studies suggest that serum sEGFR should be measured and considered prior to treatment with Cetuximab. Other research has supported this concept by showing that serum sEGFR concentration changes in response to treatment with Cetuximab.

In their second related study, published online in the current issue of the journal Biochemistry, Maihle and her team show that newly developed reagents to measure sEGFR in blood and other human tissues can detect a second unrelated cell surface protein in tumor cells: alpha-5 integrin.

"This important finding suggests that the naturally occurring sEGFR protein may play a complex role in cell adhesion and migrationtwo cellular processes important in the spread of cancer," said Maihle, who is a member of Yale Cancer Center. "Together these studies demonstrate an unanticipated level of complexity in EGFR signaling and assay development, and suggest new ways to overcome current challenges associated with clinical testing for this important cancer target."


'/>"/>

Contact: Karen N. Peart
karen.peart@hotmail.com
203-432-1326
Yale University
Source:Eurekalert

Related biology news :

1. Reforesting rural lands in China pays big dividends, Stanford researchers say
2. Chemistry researchers receive patent for new scientific measurement instrument
3. USDA researchers, collaborators sequence genomes of fungi that threaten wheat, poplars
4. Researchers get new view of how water and sulfur dioxide mix
5. OGI genomics researchers awarded $23 million
6. Columbia researchers find green roof is a cost-effective way to keep water out of sewers
7. Einstein researchers find key gene in childhood cancer
8. Researchers show heparan sulfate adjusts functions of growth factor proteins
9. Penn researchers develop technique for measuring stressed molecules in cells
10. Researchers see a picture of threat in the brain: Work may lead to new model of neuroinflammation
11. Researchers join forces to cure deadly childhood disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... November 30, 2016 The global ... players hold a dominant share in the overall market. ... International, Inc., and Merck KGaA, held a lion,s share ... Market Research observes that these companies are expected to ... products that are do not require rabbit pyrogen testing ...
(Date:11/30/2016)... 2016  Tempus, a technology company focused on ... Abramson Cancer Center have partnered to better determine ... immunotherapy treatment based on next generation genomic and ... a research collaboration, Tempus will provide sequencing and ... data to Penn. Utilizing next-generation sequencing, machine learning ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader ... the implications of the latest FDA guidance on pharmaceutical cocrystals as drug substance ... Cambridge, MA. , The event follows the successful November 15th event that ...
(Date:11/30/2016)... ... 30, 2016 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), ... today announced that all five of its validated monoclonal antibody (mAb) therapeutic candidates ... prion-like forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated that ...
Breaking Biology Technology: